血液透析患者的残余肾功能：血管紧张素转换酶抑制剂在其保留中的作用。
Residual renal function in hemodialysis patients: the role of Angiotensin-converting enzyme inhibitor in its preservation.
作者信息
Xydakis Dimitris, Papadogiannakis Apostolos, Sfakianaki Maria, Kostakis Konstantinos, Stylianou Konstantinos, Petrakis Ioannis, Ergini Antonaki, Voskarides Konstantinos, Dafnis Eugeneios
机构信息
Nephrology Department, Venizeleio Hospital, 71409 Heraklion, Crete, Greece.
Nephrology Department, University Hospital of Heraklion, Voutes, 71100 Heraklion, Crete, Greece.
出版信息
ISRN Nephrol. 2012 Dec 24;2013:184527. doi: 10.5402/2013/184527. eCollection 2013.
Abstract
Residual Renal function (RRF) has an important role in the overall morbidity and mortality in hemodialysis patients. The role of angiotensin-converting enzyme inhibitor (ACEi) in preserving renal function in chronic proteinuric nephropathies is well documented. We test the hypothesis that enalapril (an ACEi) slows the rate of decline of RRF in patients starting hemodialysis. A prospective, randomized open-label study was carried out. 42 patients were randomized in two groups either in treatment with enalapril or no treatment at all. Our study has proven that enalapril has a significant effect on preserving residual renal function in patients starting dialysis at least during the first 12 months from the initiation of the hemodialysis. Further studies are necessary in order to investigate the potential long-term effect of ACEi on residual renal function and on morbidity and mortality in patients starting hemodialysis.
摘要
残余肾功能（RRF）在血液透析患者的总体发病率和死亡率中起着重要作用。血管紧张素转换酶抑制剂（ACEi）在慢性蛋白尿性肾病中保护肾功能的作用已有充分记录。我们检验了依那普利（一种ACEi）可减缓开始血液透析患者RRF下降速率的假设。开展了一项前瞻性、随机开放标签研究。42例患者被随机分为两组，一组接受依那普利治疗，另一组不接受任何治疗。我们的研究已证明，依那普利在开始透析的患者中至少在血液透析开始后的前12个月对保留残余肾功能有显著作用。有必要进行进一步研究，以调查ACEi对开始血液透析患者的残余肾功能以及发病率和死亡率的潜在长期影响。
相似文献
1
Residual renal function in hemodialysis patients: the role of Angiotensin-converting enzyme inhibitor in its preservation.血液透析患者的残余肾功能：血管紧张素转换酶抑制剂在其保留中的作用。
ISRN Nephrol. 2012 Dec 24;2013:184527. doi: 10.5402/2013/184527. eCollection 2013.
2
3
Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.血管紧张素转换酶抑制剂对接受腹膜透析患者残余肾功能的影响。一项随机对照研究。
Ann Intern Med. 2003 Jul 15;139(2):105-12. doi: 10.7326/0003-4819-139-2-200307150-00010.
4
Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors.透析患者残余肾功能的保留：透析技术相关因素的影响
Perit Dial Int. 2001 Jan-Feb;21(1):52-7.
5
Effect of renin-angiotensin system inhibitor on residual glomerular filtration rate in hemodialysis patients.肾素-血管紧张素系统抑制剂对血液透析患者残余肾小球滤过率的影响。
Ther Apher Dial. 2012 Dec;16(6):554-9. doi: 10.1111/j.1744-9987.2012.01087.x. Epub 2012 Aug 7.
6
Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?血管紧张素转换酶抑制剂相关的血清肌酐升高：这需要引起关注吗？
Arch Intern Med. 2000 Mar 13;160(5):685-93. doi: 10.1001/archinte.160.5.685.
7
Baseline and Time-Averaged Values Predicting Residual Renal Function Decline Rate in Japanese Peritoneal Dialysis Patients.预测日本腹膜透析患者残余肾功能下降率的基线值和时间平均值
Ther Apher Dial. 2017 Dec;21(6):599-605. doi: 10.1111/1744-9987.12589. Epub 2017 Oct 19.
8
Strategies for preserving residual renal function in peritoneal dialysis patients.腹膜透析患者残余肾功能的保护策略。
Clin Kidney J. 2015 Apr;8(2):202-11. doi: 10.1093/ckj/sfu140. Epub 2015 Jan 13.
9
Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study.
Am J Hypertens. 2000 Sep;13(9):980-5. doi: 10.1016/s0895-7061(00)00287-9.
10
Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂对透析患者心血管事件及残余肾功能的影响：一项随机对照试验的荟萃分析
BMC Nephrol. 2017 Jun 30;18(1):206. doi: 10.1186/s12882-017-0605-7.
引用本文的文献
1
Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?SGLT2抑制剂在递增式血液透析患者中的疗效与安全性：最大化残余肾功能，SGLT2抑制剂是否能发挥作用？
Biomedicines. 2023 Jul 6;11(7):1908. doi: 10.3390/biomedicines11071908.
2
On the importance of the interplay of residual renal function with clinical outcomes in end-stage kidney disease.在终末期肾病的临床结局中，残余肾功能相互作用的重要性。
J Nephrol. 2022 Dec;35(9):2191-2204. doi: 10.1007/s40620-022-01388-9. Epub 2022 Jul 11.
3
Renin Angiotensin Aldosterone System Blockades Does Not Protect Residual Renal Function in Patients with Hemodialysis at 1 Year After Dialysis Initiation: A Prospective Observational Cohort Study.肾素-血管紧张素-醛固酮系统阻滞剂在透析开始 1 年后对血液透析患者残余肾功能无保护作用：一项前瞻性观察性队列研究。
Sci Rep. 2019 Dec 2;9(1):18103. doi: 10.1038/s41598-019-54572-6.
4
The protective effect of different dialysis types on residual renal function in patients with maintenance hemodialysis: A systematic review and meta-analysis.不同透析类型对维持性血液透析患者残余肾功能的保护作用：一项系统评价和荟萃分析。
Medicine (Baltimore). 2018 Sep;97(37):e12325. doi: 10.1097/MD.0000000000012325.
5
Incremental dialysis for preserving residual kidney function-Does one size fit all when initiating dialysis?增量透析以保留残余肾功能——开始透析时是否有一种通用的方法？
Semin Dial. 2018 Jul;31(4):343-352. doi: 10.1111/sdi.12701. Epub 2018 May 7.
6
Factors associated with residual urine volume preservation in patients undergoing hemodialysis for end-stage kidney disease in Kinshasa.金沙萨终末期肾病患者接受血液透析时残余尿量保留的相关因素
BMC Nephrol. 2018 Mar 20;19(1):68. doi: 10.1186/s12882-018-0865-x.
7
Effects of RAAS Inhibitors in Patients with Kidney Disease.肾素-血管紧张素-醛固酮系统（RAAS）抑制剂对肾病患者的影响。
Curr Hypertens Rep. 2017 Aug 8;19(9):72. doi: 10.1007/s11906-017-0771-9.
8
Advances in Understanding and Management of Residual Renal Function in Patients with Chronic Kidney Disease.慢性肾脏病患者残余肾功能的认识与管理进展
Kidney Dis (Basel). 2017 Jan;2(4):187-196. doi: 10.1159/000449029. Epub 2016 Sep 7.
9
Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis.开始腹膜透析患者使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂与心血管结局
Nephrol Dial Transplant. 2017 May 1;32(5):862-869. doi: 10.1093/ndt/gfw053.
10
Preservation of residual kidney function in hemodialysis patients: reviving an old concept.维持血液透析患者的残余肾功能：重拾一个古老的概念。
Kidney Int. 2016 Aug;90(2):262-271. doi: 10.1016/j.kint.2016.02.037. Epub 2016 May 12.
本文引用的文献
1
2
Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration.残余肾功能和对流在高通量血液透析及在线血液透析滤过中对β2-微球蛋白水平影响的相对重要性
Blood Purif. 2007;25(3):295-302. doi: 10.1159/000104870. Epub 2007 Jul 2.
3
Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2.残余肾功能和不同充分性指标对血液透析患者生存的相对贡献：荷兰透析充分性合作研究（NECOSAD）-2分析
J Am Soc Nephrol. 2004 Apr;15(4):1061-70. doi: 10.1097/01.asn.0000117976.29592.93.
4
Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.血管紧张素转换酶抑制剂对接受腹膜透析患者残余肾功能的影响。一项随机对照研究。
Ann Intern Med. 2003 Jul 15;139(2):105-12. doi: 10.7326/0003-4819-139-2-200307150-00010.
5
Section I. Measurement of renal function, when to refer and when to start dialysis.第一部分：肾功能的测量、何时转诊及何时开始透析。
Nephrol Dial Transplant. 2002;17 Suppl 7:7-15. doi: 10.1093/ndt/17.suppl_7.7.
6
A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients.腹膜透析患者残余肾功能与左心室肥厚之间的新型关联。
Kidney Int. 2002 Aug;62(2):639-47. doi: 10.1046/j.1523-1755.2002.00471.x.
7
Middle molecule and small protein removal in children on peritoneal dialysis.儿童腹膜透析中大分子和小分子蛋白质的清除
Kidney Int. 2002 Mar;61(3):1153-9. doi: 10.1046/j.1523-1755.2002.00216.x.
8
Impact of residual renal function in children on hemodialysis.
Pediatr Nephrol. 2001 Nov;16(11):858-61. doi: 10.1007/s004670100687.
9
Residual renal function and mortality risk in hemodialysis patients.血液透析患者的残余肾功能与死亡风险
Am J Kidney Dis. 2001 Jul;38(1):85-90. doi: 10.1053/ajkd.2001.25198.
10
Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists.肾素-血管紧张素系统（RAS）抑制的肾脏保护作用：从血管紧张素转换酶抑制剂到血管紧张素II拮抗剂。
Kidney Int. 2000 May;57(5):1803-17. doi: 10.1046/j.1523-1755.2000.00031.x.
Zotero 插件